齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
24期
3648-3649
,共2页
李子臻%简丽嫦%苏广扬%林虎
李子臻%簡麗嫦%囌廣颺%林虎
리자진%간려항%소엄양%림호
功能性消化不良%曲美布汀%多潘立酮%疗效
功能性消化不良%麯美佈汀%多潘立酮%療效
공능성소화불량%곡미포정%다반립동%료효
Functional Dyspepsia%Trimebutine%Domperidone%Effect
目的:对比分析曲美布汀、多潘立酮治疗功能性消化不良( FD )的疗效及安全性。方法将106例功能性消化不良患者分为两组:对照组53例和观察组53例。对照组给予多潘立酮,观察组给予曲美布汀,疗程均为4周。比较两组疗效、主要症状、复发情况及不良反应。结果观察组患者治疗显效率和总有效率均明显高于对照组(P<0.05);观察组患者餐后饱胀、上腹胀、嗳气、恶心、呕吐等症状发生率均明显低于对照组(P<0.05);观察组患者6个月后复发率明显低于对照组(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论曲美布汀治疗功能性消化不良的疗效优于多潘立酮,安全性好,适合临床推广应用。
目的:對比分析麯美佈汀、多潘立酮治療功能性消化不良( FD )的療效及安全性。方法將106例功能性消化不良患者分為兩組:對照組53例和觀察組53例。對照組給予多潘立酮,觀察組給予麯美佈汀,療程均為4週。比較兩組療效、主要癥狀、複髮情況及不良反應。結果觀察組患者治療顯效率和總有效率均明顯高于對照組(P<0.05);觀察組患者餐後飽脹、上腹脹、噯氣、噁心、嘔吐等癥狀髮生率均明顯低于對照組(P<0.05);觀察組患者6箇月後複髮率明顯低于對照組(P<0.05);兩組不良反應髮生率無明顯差異(P>0.05)。結論麯美佈汀治療功能性消化不良的療效優于多潘立酮,安全性好,適閤臨床推廣應用。
목적:대비분석곡미포정、다반립동치료공능성소화불량( FD )적료효급안전성。방법장106례공능성소화불량환자분위량조:대조조53례화관찰조53례。대조조급여다반립동,관찰조급여곡미포정,료정균위4주。비교량조료효、주요증상、복발정황급불량반응。결과관찰조환자치료현효솔화총유효솔균명현고우대조조(P<0.05);관찰조환자찬후포창、상복창、애기、악심、구토등증상발생솔균명현저우대조조(P<0.05);관찰조환자6개월후복발솔명현저우대조조(P<0.05);량조불량반응발생솔무명현차이(P>0.05)。결론곡미포정치료공능성소화불량적료효우우다반립동,안전성호,괄합림상추엄응용。
Objective Contrastively analyze the effect and security of trimebutine and domperidone on functional dyspepsia ( FD ) .Methods Divided 106 cases of FD patients into observation group and control group, with 53 cases in each group.Gave domperidone to the control group and trimebutine to the observation group with a four-week course of treatment respectively.Compared the effect, cardinal symptom, recurrence and untoward effect of the groups.Results The significant efficiency and total effectiveness of the treatment in the observation group was apparently higher than that in the control group (P<0.05);Occurrence rate of symptoms including postprandial fullness, epigastric distention, belching, nausea, emesis in the observation group was apparently lower than that in the control group ( P<0.05 ); Recurrence rate in the observation group after 6 months was apparently lower than that in the control group ( P <0.05 ); There was no significant difference between the groups in untoward effect occurrence rate (P>0.05).Conclusions Trimebutine shows better effect on FD than Domperidone with higher security, and is suitable for wide clinic application.